Gilead Implements Emergency Disaster Response Procedures to Ensure Medicine Access

UPDATE: FOSTER CITY, Calif., September 7, 2017 — Gilead Sciences announces $1 million in funding to help HIV organizations impacted by Hurricanes Harvey and Irma. For further details, see press releases by Gilead partners NMAC and AIDS United.

FOSTER CITY, Calif., September 1, 2017 — Gilead Patient Support Programs have been prepared to work with local healthcare practitioners to provide free medicine for individuals in affected areas who meet eligibility requirements. Patients or their providers can request assistance by contacting the applicable Gilead Patient Support Program, where their eligibility for assistance will be assessed. Once approved, patients will be sent up to a 30-day supply of their medication. Patients can find information on Gilead Patient Support Programs by visiting http://www.gilead.com/responsibility/us-patient-access.

“We’ve seen in the past that extreme, severe weather events can threaten health systems and interrupt access to care,” says Jim Meyers, Executive Vice President, Commercial Operations. “We’ve prepared our programs to work with healthcare providers and people at risk of a lapse in therapy to ensure continued access to Gilead medicines.”

In addition to enacting the disaster response procedures, Gilead Sciences has also made a contribution to the Houston Mayor Sylvester Turner’s Hurricane Relief Fund. This fund will be administered by the Greater Houston Community Foundation, and will be used to help flood victims.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases worldwide.  Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.